METASTATIC CERVICAL CANCER
Clinical trials for METASTATIC CERVICAL CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CERVICAL CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CERVICAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for tough cervical cancers
Disease control Recruiting nowThis study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with advanced cervical cancer that has not responded to initial treatment. The goal is to see if this combination can shrink tumors or slow cancer growth. About 35 participants will receive the t…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
New hope for advanced cervical cancer: phase 3 trial of SHR-A2102 begins
Disease control Recruiting nowThis study tests a new drug, SHR-A2102, against standard chemotherapy in about 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and immunotherapy. The goal is to see if SHR-A2102 helps people live longer. Participants must hav…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
New combo therapy offers hope for advanced cervical cancer patients
Disease control Recruiting nowThis clinical trial is testing a new treatment approach for people with cervical cancer that has spread, come back, or not gone away after standard treatment. The study combines immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without another targeted drug (…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
New combo therapy aims to revive immune attack on hard-to-treat cervical cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (PRGN-2009) to the existing immunotherapy pembrolizumab can shrink tumors in people with advanced cervical cancer that no longer responds to pembrolizumab alone. About 24 adults with HPV-positive, recurrent or metastatic cervic…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE2 • Sponsor: Precigen, Inc • Aim: Disease control
Last updated May 26, 2026 08:28 UTC